Articles dans des revues avec comité de lecture (158)
  1. 98. Idrissi Kaitouni, M., & Roumeguere, T. (2009). Le point sur les traitements du cancer de prostate en Belgique. Revue médicale de Bruxelles, 30(4), 270-278.
  2. 99. Roumeguere, T., Zouaoui Boudjeltia, K., Hauzeur, C., Schulman, C., Vanhaeverbeek, M., & Wespes, E. (2009). Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia? BJU international, 104(4), 511-517. doi:10.1111/j.1464-410X.2009.08418.x
  3. 100. Peltier, A., Van Velthoven, R., & Roumeguere, T. (2009). Current management of erectile dysfunction after cancer treatment. Current opinion in oncology, 21(4), 303-309. doi:10.1097/CCO.0b013e32832b9d76
  4. 101. Roumeguere, T., Zouaoui Boudjeltia, K., & Vanhaeverbeek, M. (2009). Effect of LDL modified by myeloperoxidase-H2O2-Cl(-) system on intracellular cyclic guanosine monophosphate level of endothelial cells: a link to erectile dysfunction? European urology, 55(3), 754-755. doi:10.1016/j.eururo.2008.09.038
  5. 102. Goris, M., Roumeguere, T., Addla, S. K., Schulman, C., & Djavan, B. (2009). Phytotherapy in Chronic Prostatitis. Current prostate reports, 7, 39-43. doi:10.1007/s11918-009-0007-9
  6. 103. Perimenis, P., Roumeguere, T., Heidler, H., Roos, E., Belger, M., & Schmitt, H. (2009). Evaluation of patient expectations and treatment satisfaction after 1-year tadalafil therapy for erectile dysfunction: the DETECT study. Journal of Sexual Medicine, 6(1), 257-267. doi:10.1111/j.1743-6109.2008.01027.x
  7. 104. Idrissi Kaitouni, M., & Roumeguere, T. (2009). Les traitements du cancer de prostate. Revue médicale de Bruxelles, 30(4), 270-278.
  8. 105. Roumeguere, T. (2009). Traitement médical et chirurgical du priapisme spontané et iatrogène. Encyclopédie médico-chirurgicale. Urologie, 18(380), 10.
  9. 106. Roumeguere, T., Zouaoui Boudjeltia, K., Hauzeur, C., Ramal, A., Schulman, C., Vanhaeverbeek, M., Ducobu, J., & Wespes, E. (2008). Diminution du rapport ApoB/ApoA-1 et amélioration du risque cardiovasculaire : effet pleïotropique du tadalafil ? Étude préliminaire sur volontaires sains. Progrès en urologie, 18(13), 1087-1091. doi:10.1016/j.purol.2008.09.057
  10. 107. Roumeguere, T. (2008). Editorial comment on: Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy. European urology, 54(4), 916-917. doi:10.1016/j.eururo.2007.11.010
  11. 108. Roumeguere, T., Verheyden, B., Arver, S., Bitton, A., Belger, M., & Schmitt, H. (2008). Therapeutic response after first month of tadalafil treatment predicts 12 months treatment continuation in patients with erectile dysfunction: results from the DETECT study. Journal of Sexual Medicine, 5(7), 1708-1719. doi:10.1111/j.1743-6109.2008.00790.x
  12. 109. Lemy, A., Wissing, K. M., Rorive, S., Zlotta, A., Roumeguere, T., Muniz Martinez, M. C., Decaestecker, C., Salmon, I., Abramowicz, D., Vanherweghem, J.-L., & Nortier, J. (2008). Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up. American journal of kidney diseases, 51(3), 471-477. doi:10.1053/j.ajkd.2007.11.015
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Suivant >>